Strontium chloride (Sr-89), initially FDA-approved in 1993, is used as a paliative therapeutic option to help relieve the pain from bone metastases. Strontium chloride is mainly used in cases of metastatic castrate-resistant prostate cancer. Bone metastases is a common and severe complication presented in advanced stages of the disease. It is usually presented mainly in patients with prostatic and breast cancer, as well as in cancer of lung, bladder and thyroid. There has been some cases of apparent tumor regression which has given it a potential tumoricidal effect. The directory classifies it as a commercial API with a mineral/inorganic source/manufacturing origin. Other names for this substance include strontium chloride, 89Sr-labeled and Strontium chloride sr 89 [USAN]. Its PubChem CID is 5388879.
Strontium chloride Sr-89
| CAS No | 38270-90-5 |
|---|---|
| Molecular Formula | Cl2Sr |
| Molecular Weight | 159.81 g/mol |
| Synonyms | strontium-89(2+);dichloride |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Strontium chloride (Sr-89), initially FDA-approved in 1993, is used as a paliative therapeutic option to help relieve the pain from bone metastases. Strontium chloride is mainly used in cases of metastatic castrate-resistant prostate cancer.
The listed CAS number is 38270-90-5.
The listed molecular formula is Cl2Sr.
The listed molecular weight is 159.81 g/mol.
strontium-89(2+);dichloride.
The source lists strontium chloride, 89Sr-labeled and Strontium chloride sr 89 [USAN].